1Jones AL,Smith IE,O'Brien MER,et al. Phase Ⅱ study of continous infusion fluorourcil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol,1994,12(6) :1 259.
2O' Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase Ⅱ study of Xeloda(capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged≥55 years. Proc Am Soc Clin Oncol, 1998,17 : 103a.
3Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs,2000,18(4) :343.
4Talbot DC, Moiseyenko V, O'Reilly SM, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracydines. Br J Cancer, 2002,86 ( 9 ) : 1 367.
5Blum JL,Jones SE, Buzdar AU, et al. Muhicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999,17(2) :485.
4HENDERSON I C,BERRY D A,DEMETRI G D,et al.Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer[J].J Clin Oncol,2003,21 (6):976-983.
5HEYS S D,SARKAR T,HUTCHEON A W.Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer[J].Expert Opin Pharmacother,2004,5 (10):2147-2157.
6KUERER H M,NEWMAN L A,SMITH T L,et al.Clinical course of breast cancer patients with complete pathologic primary tumor and auxillarylymph node response to doxorubicin based neoadujvant chemotherapy[J].J Clin Oncol,1999,17(2):460-469.
7DEO S V S,BHUTANI M,SHUKLA N,et al.Randomized trial comparing neo adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer(T4bN0-2M0)[J].Oncol Surg,2003,84(1):192-197.
8INAJI H,KOMOIKE Y,MOTOMURA K,et al.Breast conserving treatment after neoadjuvant chemotherapy in large breast cancer[J].Breast Cancer,2002,9(1):20-25.
9ALBA E,MARTIN M,RAMOS M,et al.Multicenter randomized trial comparing sequential with concomitan administration of doxorubicin and docetaxel as firstline treatment of metastatic breast cancer:a Spanish Breast Cancer Research Group (GEICAM29903) phse Ⅲ study[J].J Clin Oncol,2004,22(13):2587-2593.
10BONNETERRE J,DIERAS V,TUBIANA H M,et al.Phase Ⅱ multicent rerandomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer[J].Br J Cancer,2004,91(8):1466-1471.
